Abstract 4377: AN9025, an orally bioavailable pan-RAS(ON) inhibitor with potent, broad-spectrum anti-tumor activity
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-4377
Abstract: RAS mutations drive approximately 30% of human cancers, representing a critical unmet clinical need. AN9025, an oral RAS (ON) inhibitor, with best-in-class potential, demonstrates picomolar potency against RAS-dependent tumor cell lines, showing greater potency than… read more here.
Keywords: an9025; tumor; cell; pan ras ... See more keywords